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Abstract
Multidrug resistance (MDR)-1-P-glycoprotein (P-gp) is
a drug-transporting protein that is abundantly present in
biliary ductal cells and epithelial cells lining the gastrointes-
tinal tract. Here, we have determined the role of P-gp in the
metabolic disposition of the antineoplastic agent docetaxel
(Taxotere) in humans. Pharmacokinetic profiles were eval-
uated in five cancer patients receiving treatment cycles with
docetaxel alone (100 mg/m2 i.v. over a 1-h period) and in
combination with a new potent inhibitor of P-gp activity,
R101933 (200–300 mg b.i.d.). The terminal disposition half-
life and total plasma clearance of docetaxel were not altered
by treatment with oral R101933 (P > 0.27). The cumulative
fecal excretion of docetaxel, however, was markedly reduced
from 8.47 6 2.14% (mean 6 SD) of the dose with the single
agent to less than 0.5% in the presence of R101933 (P 5
0.0016). Levels of the major cytochrome P450 3A4-mediated
metabolites of docetaxel in feces were significantly increased
after combination treatment with R101933 (P 5 0.010),
indicating very prominent and efficient detoxification of
reabsorbed docetaxel into hydroxylated compounds before
reaching the systemic circulation. It is concluded that intes-
tinal P-gp plays a principal role in the fecal elimination of
docetaxel by modulating reabsorption of the drug after
hepatobiliary secretion. In addition, the results indicate that
inhibition of P-gp activity in normal tissues by effective
modulators, and the physiological and pharmacological con-
sequences of this treatment, cannot be predicted based on
plasma drug monitoring alone.
Introduction
Acquired or intrinsic resistance of malignant cells to tax-
anes and other naturally occurring anticancer drugs has been
linked to the so called “classical” mechanism of MDR,3 which
can cause decreased intracellular concentrations of these drugs
(1). This MDR phenotype is characterized by increased levels of
P-gp, a member of the ATP binding cassette superfamily of
transmembrane transport proteins with Mr 170,000 encoded by
the MDR1 gene, which acts as an energy-dependent drug-efflux
pump with broad substrate specificity (1). P-gp expression has
been found in nearly all of the tumor types, ranging from
leukemia to carcinoma, and it has also been reported in a
number of normal tissues, mainly in specialized epithelial cells
with secretory functions including the apical biliary surface of
hepatocytes and epithelial cells of the intestinal tract (2). The
physiological functions of P-gp are still speculative at this time,
but possibilities include involvement in the protection of epi-
thelial mucosal cells in the gastrointestinal tract from xenobiot-
ics, in transport of steroids in the adrenals and bile salts in the
liver, in protein secretion in the kidneys (3), and, most recently
discovered, in migration of dendritic cells and T-lymphocytes
out of the skin (4). In addition, the expression of P-gp in the
capillary endothelial cells forming the blood-brain and the
blood-testis barrier apparently protects these organs from exog-
enous toxins, and thus contributes to the role of these anatomical
sites as drug sanctuaries (reviewed in Ref. 5).
Several studies have shown that P-gp-mediated MDR is of
clinical significance, and this observation has stimulated a
search for noncytotoxic agents that can reverse this resistance
phenomenon (6, 7). Clinical trials performed thus far with
identified P-gp inhibitors given in combination with anticancer
drugs, however, have raised important issues regarding the
safety of the chemotherapeutic treatment because of drug inter-
actions that increased or changed the spectrum of associated
toxic side effects (8, 9). The results of these clinical trials in
combination with the poorly defined pharmacological and phys-
iological function of P-gp in humans emphasize the need to
perform studies to further evaluate the role of P-gp in the
disposition of substrate drugs. The importance of these studies is
further underscored by the previous use of anticancer drugs that
are rather poor substrates of P-gp given with nonspecific inhib-
itors of P-gp (9). Thus, in the present study, we evaluated the
role of P-gp in the plasma disposition and fecal elimination
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pathways of docetaxel, one of the best known substrates of P-gp
(10), in humans using a combined treatment with the new p.o.
administered P-gp inhibitor R101933 as a model compound.
Materials and Methods
Drug Administration. Docetaxel (Rhoˆne-Poulenc Ro-
rer, Antony Cedex, France) was supplied as a concentrated
solution in polysorbate 80 (40 mg/ml; Taxotere) and was ad-
ministered to five cancer patients at a dose of 100 mg/m2 as
a 1-h i.v. infusion. Three weeks later, the same dose was
administered to each patient 1 h after intake of R101933 on
day 3. All of the patients received premedication with dex-
amethasone (8 mg b.i.d.), starting 24 h prior to infusion of
docetaxel and continuing for 4 days thereafter. R101933 (methyl
6,11-dihydro-11-(1-[2-[4-(2-quinolinyl-methoxy)phenyl]ethyl]-
4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxyl-
ate), an agent acting as a specific antagonist of P-gp, was
supplied by Janssen Research Foundation (Beerse, Belgium) as
an oral solution containing 10 mg/ml of the active compound in
15% hydroxypropyl-b-cyclodextrin. The drug was administered
p.o. twice daily for 5 consecutive days (i.e., days 1–5) with 200
ml of water, at least 1 h after a meal. The clinical protocol was
approved by the institutional ethics committee, and signed in-
formed consent was obtained from each participant before en-
tering the study.
Sample Collection and Processing. Blood specimens
were acquired in all of the patients during both treatment
courses. Sample volumes of ;6 ml were drawn directly from a
peripheral venous access device into tubes containing lyophi-
lized sodium heparin as an anticoagulant. Blood samples were
collected immediately before infusion, and at 0.5, 1, 1.25, 1.5, 2,
3, 7, 11, 23, and 31 h after the start of infusion. All of the
samples were centrifuged immediately for 10 min at 1000 3 g
to yield plasma, which was stored frozen at 220°C in polypro-
pylene vials until the time of analysis.
Complete stool collections for docetaxel analysis were
obtained for the duration of the study (i.e., up to 31 h after the
start of drug administration). This space of time was chosen
based on previous fecal excretion studies with the structural
related agent paclitaxel (11). Fecal specimens were collected in
polystyrene containers and stored immediately at 220°C.
Weighted feces samples were homogenized individually in 3
volumes of a phosphate buffer [containing 0.01 M potassium
phosphate, 0.137 M sodium chloride and 2.7 mM potassium
chloride in the presence of 0.05% (w/v) glucose (pH 7.4)] using
five 1-min bursts of an Ultra-Turrax T25 homogenizer (IKA-
Labortechnik, Dottingen, Germany) operating at 20,500 rpm.
Aliquots of 500 ml of feces homogenates were diluted with
human plasma (1:1, v/v) and stored frozen at 280°C prior to
further processing.
Analytical Methods. A pure reference standard of do-
cetaxel (batch: 14PROC9230; purity: 98.0% by HPLC) was
kindly supplied by Rhoˆne-Poulenc Rorer, and was used as
received. Plasma concentrations of docetaxel were determined
by a validated HPLC assay with mass-spectrometric detection,
with a lowest limit of quantitation of 1 ng/ml. Samples (200 ml)
were pretreated by solid-phase extraction using end-capped
Bond Elut nitrile microcolumns (Varian, Harbor City, CA). A
stainless steel analytical column (100 3 4.6 mm, internal diam-
eter) packed with 3 mm of Hypersil BDS C18 material (Alltech,
Breda, the Netherlands) was used for chromatographic separa-
tion, and gradient elution was performed with a mixture of
acetonitrile and 0.02 M ammonium acetate (pH 4.0) at a flow
rate of 0.8 ml/min. Paclitaxel (Bristol-Myers Squibb, Walling-
ford, CT) was used as internal standard.
Authentic reference standards of the docetaxel metabolites
M1, M2, M3, and M4 (Fig. 1) were obtained after isolation and
purification of a patient fecal sample, as described previously
(12), and their concentrations in feces homogenates were deter-
mined by reversed-phase HPLC with UV detection using a
modification of a procedure described elsewhere (13). In brief,
quantitative extraction was achieved by a single solvent extrac-
tion of 0.5-ml samples with a mixture of acetonitrile-n-butyl
chloride (1:4, v/v). Chromatography was performed at 60°C
using an Inertsil ODS-80A column (150 3 4.6 mm; 5-mm
particle size; GL Science, Tokyo, Japan) protected by a Lichro-
spher 100 RP-18 end-capped-guard column (4.0 3 4.0 mm;
5-mm particle size; Merck, Darmstadt, Germany), and a 1-h
exponential gradient elution (45–75%; 1 ml/min) of methanol in
water-tetrahydrofuran-aqueous ammonium hydroxide (97.4:2.5:
0.1, v/v/v) at pH 6.0. The column effluent was monitored at a
wavelength of 230 nm.
Concentrations of R101933 and its esterase-mediated car-
boxylic acid metabolite, R102207, were determined by a vali-
dated HPLC method involving solid-phase extraction on Bond-
Elut Certify microcolumns (Varian). Standard curves were
Fig. 1 Chemical structures of docetaxel (A) and its major cytochrome
P450 3A4-mediated metabolite M4 (B).
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prepared in drug-free human plasma and were expanded to
encompass concentrations between 2 and 10,000 ng/ml A 1-ml
aliquot of standard or plasma sample was mixed with 3 ml of 1
M aqueous acetic acid and 100 ml of internal standard solution
(R125026 in acetonitrile at 10 mg/ml). Before loading, columns
were preconditioned with 3 ml of ethanol, 3 ml of water, and 1
ml of 1 M of aqueous acetic acid. Consecutive washing steps
involved 3 ml of water, 1 ml of aqueous acetic acid, and 3 ml of
ethanol, and elution was performed with 3 ml of a mixture of
ethanol-ammonia (98:2, v/v). Samples were dried under nitro-
gen at 65°C and redissolved in 100 ml of 0.02 M ammonium
formate (pH 4.0)-acetonitrile-ethanol (50:25:25, v/v/v). Chro-
matography was performed on a column (100 3 4.6 mm)
packed with 3-mm Hypersil BDS C8 material (Alltech), and
gradient elution (0.8 ml/min) with a mixture of 0.02 M ammo-
nium formate (pH 4.0), acetonitrile, and ethanol. UV absorption
measurements were performed at a wavelength of 270 nm.
Determination of analyte concentrations was based on log-
transformed peak areas of R101933 and R102207 and the in-
ternal standard versus nominal concentrations by interpolation
using linear regression analysis.
Pharmacokinetic Analysis. Individual plasma concen-
tration-time curves of docetaxel were analyzed by a two-
compartmental model using the software package WinNonlin
(Pharsight, Mountain View, CA). All of the curves were fitted
using the actual infusion duration and blood sampling times.
Pharmacokinetic parameters were calculated by standard meth-
ods. To test parameter differences for statistical significance
among treatment courses, a two-tailed paired Student’s t test
was performed. P values of less than 0.05 were considered
statistically significant.
In Vitro Studies. A functional in vitro study was per-
formed to evaluate whether oral R101933 in humans yields
plasma levels that are capable of inhibiting P-gp function in
tumor cells. The parental human ovarian carcinoma cell line
A2780 (P-gp-negative) and the derived anthracycline-resistant
lines A2780T100 and 2780AD (both P-gp-positive), developed
by transfection of P-gp and step-wise exposure to doxorubicin,
respectively, were grown and maintained in colorless RPMI
1640 (Brunschwig, Amsterdam, the Netherlands). Cells were
kept in continuous logarithmic growth at 37°C in a humidified
atmosphere in 5% CO2/95% air in medium supplemented with
10% (w/v) heat-inactivated bovine calf serum (Hyclone, Logan,
UT), penicillin, streptomycin, and L-glutamine. Exponentially
grown cells were trypsinized, packed by centrifugation for 5 min
at 1500 3 g, and washed twice with medium. The cells were
counted microscopically and transferred to protein-free RPMI to
dilutions containing 4.0 3 105 cells per ml. Inhibition of P-gp-
mediated drug efflux in each of the cell lines was evaluated
using a daunorubicin (final concentration, 1 mg/ml) retention
assay, in the presence of various concentrations of R101933,
ranging from 1 to 1000 ng/ml. Preliminary time course exper-
iments revealed that at a given R101933 concentration, dauno-
rubicin uptake in the cells did not change after 90 min, at which
time equilibrium was reached. Thus experiments were carried
out with a 2-h incubation period at 37°C, using 0.5-ml aliquots
of the cell suspension in 4.5-ml polypropylene screw-cap tubes
(Greiner, Alphen aan den Rijn, the Netherlands). The addition of
R101933 was done after extraction of the compound from a
human plasma matrix or patient sample using a mixture of
acetonitrile and n-butyl chloride (1:4, v/v), and reconstitution of
dried extracts in neat medium by agitation. During the incuba-
tion period, tubes were gently vortex-mixed at 30-min intervals
to prevent clogging of the cells. Intracellular levels of daunoru-
bicin were measured using flow cytometry with the aid of a
fluorescence-activated cell sorter. The fluorescence intensity in
the resistant cell lines relative to that observed in the A2780
parental cell line in the absence of R101933, expressed as
percentage, was plotted relative to the R101933 concentration.
Results
Plasma Pharmacokinetics. The results of paired
plasma concentration-time profiles of unchanged docetaxel
given with and without cotreatment of oral R101933 were
remarkable similar for all of the patients studied (Fig. 2). The
mean pharmacokinetic parameters of docetaxel for both treat-
ment courses are summarized in Table 1. There were no
statistically significant differences in any of the studied do-
cetaxel kinetic parameters, including the AUC and terminal
disposition half-life, which suggested that R101933 did not
influence the disposition of the taxane in the systemic circu-
lation. The observed peak plasma concentrations of R101933
were in the range of 25.3–168 ng/ml and 83.1–142 ng/ml in
the absence and presence of docetaxel, respectively. Concen-
trations of R101933 in this range were observed to inhibit
P-gp-mediated daunorubicin efflux in two cell lines with
known expression of P-gp and resistance to anthracyclines
(Fig. 3). In all of the patients, there was extensive formation
of the pharmacologically inactive compound, R102207, re-
sulting from an ester hydrolysis, with peak levels approxi-
mately 75-fold higher (range, 33–124) than that of the parent
drug.
Fecal Elimination. In humans, excretion of docetaxel
via the feces is a major route of drug elimination (12, 14). To
evaluate the effects of P-gp inhibition on elimination path-
ways of docetaxel, feces samples were collected over a
Fig. 2 Plasma concentration versus time profiles of docetaxel in five
patients treated with docetaxel alone (E;100 mg/m2 as a 1-h i.v. infu-
sion) or in combination with oral R101933 (F; 200 or 300 mg b.i.d.).
Data are presented as mean values (symbols) 6 SD (error bars).
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period of 31 h from all five of the patients during both
treatment courses with and without R101933. Preliminary
insight obtained from work of our laboratory into the com-
position of docetaxel metabolites present in feces samples
indicated that apart from docetaxel, seven chromatographic
peaks absorbed at 230 nm, the peak wavelength of taxane
derivatives. Structural identification using HPLC and off-line
mass spectrometry showed that the major peak was M4, a
known metabolite of docetaxel resulting from hydroxylation
reactions on the tert-butyl propionate side chain (15). Using
reference standards, three of the minor peaks were identified
as metabolites resulting from oxidation of one of the methyl
groups on the tert-butyl propionate side chain (M2), and
spontaneous cyclization of this alcohol derivative to the two
diastereoisomers M1 and M3.
In patients treated with docetaxel alone, 8.47 6 2.14%
(mean 6 SD; n 5 5) of the administered dose was excreted in
the first 31 h as the parent drug, whereas 13.3 6 1.81% of the
dose could be accounted for by metabolite M4 (Table 1). The
total fecal recovery of the metabolites M1, M2, and M3 was
very low in all of the patients (less than 0.5% of the dose; data
not shown) and apparently the compounds play only a minor
role in the overall drug disposition. In the same group of
patients, coadministration with R101933 resulted in markedly
reduced fecal excretion of unchanged drug to less than 0.5% of
the administered dose (P 5 0.0016). In contrast, however, the
excretion of metabolite M4 was significantly increased in all of
the patients to 20.1 6 4.39% of the dose (P 5 0.010). These
data clearly show that R101933 administered p.o. causes a
profound alteration of P-gp-mediated intestinal reabsorption of
docetaxel, without modifying the drug’s kinetic behavior in
plasma.
Discussion
In the present study we have shown that intestinal P-gp
plays a principal role in the fecal elimination pathways of
docetaxel without modifying the pharmacokinetic behavior of
the drug in the systemic circulation. Previous investigations
have shown a major role of the cytochrome P450 3A4 isozymes
in docetaxel metabolism. In humans, the principal biotransfor-
mation routes involve hydroxylation of the tert-butoxy function
in the C13 side chain, followed by a spontaneous cyclization
reaction (15). The four principal metabolites resulting from this
pathway have substantially less cytotoxic activity on tumor and
nonmalignant hematopoietic cells as compared with the parent
drug (12). Fecal excretion of docetaxel and its metabolites has
been previously reported in two other cases (14, 15), and in
both, M4 was the main metabolite, very similar to our present
findings, and accounted for a larger fraction of the recovered
dose than docetaxel itself. Interestingly, this metabolite can only
be detected in the systemic circulation in about 30% of the
patients treated with docetaxel at a dose of 100 mg/m2 and
reaches peak plasma levels ranging form only 22 to 230 ng/ml
(16). This makes it very likely that metabolite M4 is very
efficiently excreted through a biliary secretion pathway into the
intestinal lumen immediately after its formation, and that reab-
sorption is low. In our patients, we observed that coadministra-
tion with R101933 had a marked effect on the fecal elimination
of docetaxel, changing from excretion partly as unchanged drug
in case of single-agent administration to almost exclusively
through metabolic breakdown (mainly to M4) in the combina-
tion treatment. The similarity of the terminal disposition phases
Fig. 3 Modulation of cellular daunorubicin uptake by R101933 as
measured by a change in the fluorescence intensity in the P-glycopro-
tein-expressing and anthracycline-resistant cell lines A2780T100 () and
2780AD () relative to that observed in the A2780 parental cell line (F)
in the absence of R101933. Experiments were carried out with a 2-h
incubation period at 37°C with R101933 present at various concentra-
tions. Data points, expressed as percentage, are mean values of at least
three independent experiments performed in duplicate; bars, SEs. Gray
box, the range of R101933 peak levels observed in the five patients after
treatment with a p.o. dose of 200 or 300 mg. Over the entire drug
concentration range, substantial increases in intracellular fluorescence,
induced by R101933-mediated inhibition of P-glycoprotein activity,
could be detected.
Table 1 Disposition and elimination kinetics of docetaxel in the
absence or presence of oral R101933a
Parameter Without R101933 With R101933 Pb
Plasma
Docetaxel
AUCc (mgzh/ml) 3.62 6 0.66 4.22 6 0.97 0.33
(3.04–4.50) (3.09–5.63)




fef (%) 8.47 6 2.14 0.45 6 0.24 0.0016
(5.92–11.3) (0.13–0.72)
M4
fef (%) 13.3 6 1.81 20.1 6 4.39 0.010
(11.3–15.5) (16.8–27.4)
a Data were obtained from five cancer patients receiving a 1-h i.v.
infusion of docetaxel at 100 mg/m2 either alone or in combination with
200 or 300 mg of R101933 given p.o. The kinetic terms are mean
values 6 SD, with ranges in parentheses.
b Probability value versus control without R101933 (paired two-
sided Student’s t test).
c AUC, area under the plasma concentration of docetaxel versus
time curve; t1⁄2(b), terminal disposition half-life of docetaxel; fef, per-
centage of the absolute docetaxel dose excreted in the feces within 31 h
after administration of indicated drug.
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in plasma of docetaxel between treatment courses indicate that
the reduced fecal excretion of the parent drug in the patients
receiving R101933 is unlikely to be related to diminished (P-
gp-mediated) biliary secretion. This is also in line with recent
preclinical studies performed in mice lacking mdr1 (drug-trans-
porting) P-gp, which indicates that these proteins are not essen-
tial per se for normal hepatobiliary secretion of the related
compound, paclitaxel (17). After biliary secretion of docetaxel
given in combination with R101933, reabsorption of drug from
the intestinal lumen seems to be a very efficient process. This
does not, however, result in increased plasma levels because of
a virtually complete first-pass extraction and/or docetaxel me-
tabolism in the liver and intestinal mucosa, which also has
significant expression of cytochrome P450 3A isozymes (Ref. 9;
see Fig. 4 for a schematic representation of the role of intestinal
P-gp in docetaxel metabolism and excretion). These findings
lend further support to previous observations that the absorption
of substrate drugs from the intestines can be increased by
concomitant administration with P-gp inhibitors (reviewed in
Ref. 18).
The present data also raise important questions regarding
the role of endogenously expressed P-gp (for instance in the bile
canaliculi, kidneys, and intestinal epithelial cells) in the phar-
macokinetics of substrate drugs in plasma. It has been shown
previously that R101933 does not interfere with docetaxel me-
tabolism in preclinical systems, it does not induce cytochrome
P450 isozymes, and the major metabolic routes of the modulator
itself is ester hydrolysis, which is independent of cytochrome
P450 activity.4 Our results of unaltered plasma concentrations of
docetaxel in the combination with R101933 is consistent with
the postulated concept that pharmacokinetic interference be-
tween P-gp modulators and anticancer drugs is the result of
4 G. Mannens, unpublished data (on file, Janssen Research Foundation).
Fig. 4 Schematic representation of the role of intestinal P-glycoprotein in docetaxel metabolism and elimination in humans. ‹ , model of the
hepatic-cellular plate showing the bile collecting system with hepatic metabolism of docetaxel from the systemic circulation or the portal vein after
reabsorption following the biliary secretion by cytochrome P450 3A4 isozymes into metabolite M4 and its subsequent secretion in the terminal bile
duct. › , model of the intestinal epithelium showing reuptake of docetaxel into the intestinal lumen, P-glycoprotein-mediated efflux of docetaxel and
its inhibition by R101933 and intestinal metabolism by the cytochrome P450 3A4 enzyme system. p, sites of drug measurement; Doc, docetaxel;
CYP3A4, enzymes of the cytochrome P450 family isoform 3A4.
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competition for (cytochrome P450) enzymes involved in drug
metabolism (8). This is also in keeping with previous knowledge
from data generated in P-gp knock-out mice (5, 17–19) and
sheds light on some important mechanistic aspects of drug-drug
interactions. Most importantly, our data clearly indicate that
inhibiting P-gp function in normal tissues by administration of
an effective modulator, the physiological and pharmacological
consequences of this treatment cannot be predicted based on
plasma drug measurement alone.
Given the dominant pharmacological role of intestinal P-gp
activity in the efficiency and pattern of fecal excretion of do-
cetaxel, we expect that the possibility to inhibit its activity
completely with a p.o. administered P-gp modulator as demon-
strated in this study can have important pharmacological appli-
cations. One of these applications is to increase the oral bio-
availability of taxane drugs, which are known to display poor
absorption characteristics after oral drug administration (19).
Indeed, recent experimental data have shown that coadministra-
tion of oral PSC833 or cyclosporin A (both substrates of cyto-
chrome P450 3A4 isozymes) increased the AUC for paclitaxel
in mice more than 10-fold (20), and preliminary findings from
the same group indicate that the same applies to paclitaxel
administered to cancer patients (21). On the basis of our present
data, which show a very prominent and efficient detoxification
of reabsorbed docetaxel into hydroxylated metabolites before it
can reach the systemic circulation, we expect that this approach
of increasing drug bioavailability is unlikely to succeed unless
the modulator significantly interferes with docetaxel metabo-
lism.
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